Navigation Links
CSL Behring Signs Agreements With Canadian Blood Services and Hema-Quebec to Supply Life-Saving Therapies
Date:4/3/2008

in theory, the agent responsible for the Creutzfeldt-Jacob disease.

In some cases, patients may develop inhibitors of Factor VIII. These correspond to a patient's own antibodies which are directed against the Factor VIII present in Helixate(R) FS or Humate-P(R).

For more information about Helixate(R) FS and Humate-P, please contact: CSL Behring Canada, 1-866-773-7721.

About Immune Deficiency Disorders

Primary Immune Deficiencies (PIDs) are a group of disorders, usually genetic in nature, that cause a malfunction of the immune system, either in part or in totality, thus preventing the patient from fighting off infections caused by everyday microorganisms. For individuals with PID - many of them children - infections may not improve, as it would generally be expected, following an antibiotic treatment; this can in turn lead to recurrent infections. As a result, patients may face repeated rounds of antibiotics or, in some severe cases of PID, be hospitalized repeatedly for treatment. Repeated infections can lead to organ damage, which, over time, can become life-threatening. Some infections, such as meningitis, may even result in death.

Nearly 100 types of PIDs exist. Most are inherited, but in some cases the cause is unknown. No single treatment works for all of the different types. Infusions of replacement antibodies (immunoglobulins or Ig) can help supplement the immune system to prevent infection in nearly three-quarters of those people living with PID whose disease is tied to an antibody deficiency.

About Privigen(R) and Vivaglobin(R) Privigen(R) and Vivaglobin(R) are human plasma-derived therapeutic products containing a broad spectrum of immunoglobulins administered as replacement therapy in order to increase the antibody levels in patients with immune deficiencies.

Privigen(R) is an immunoglobulin (Ig) preparation designed to be administered via intravenous infusion. What sets it apart from other intravenous Ig
'/>"/>

SOURCE CSL Behring
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. CSL Behring Expands Into Middle East Market with Haemate(R) P
2. Siemens Completes Acquisition of Dade Behring
3. Siemens Receives EU Antitrust Clearance for Acquisition of Dade Behring
4. AMDL Signs Exclusive Licensing Agreement for Human Papilloma Virus Diagnostic Test Kit in Certain Asian Countries
5. Pharsight Signs Two New DMX(R) License Customers
6. Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS
7. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in Germany
8. Cardiac Science Signs Letter of Intent With Misys Healthcare Systems to Connect With Their EMR Systems
9. WaferGen Signs Exclusive Distribution Agreement for SmartSlide(TM) Micro-Incubation System in United Kingdom and France
10. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals
11. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Calif. (PRWEB) , ... July 02, 2015 , ... Sleepless ... improve an individual’s quality of sleep, launched its Indiegogo campaign on June 23. Sound ... Luzi's voice command technology makes it effortless to use, while the integration of the ...
(Date:7/1/2015)... PARIS , July 1, 2015 ... key developer of biotech crops, today announce a ... generations of insect control traits. "Growers ... the realities of advancing insect resistance. We are ... insect control technology with Genective,s capability in developing ...
(Date:7/1/2015)... India , July 1, 2015  Strand Life ... generation sequencing technology to empower cancer care, today announced ... chief executive officer. In his expanded role as now ... strategy, business expansion and worldwide operations effective immediately.  Dr. ... chairman and CEO since its founding in 2000, will ...
(Date:7/1/2015)... CHANDLER, Ariz. , July 1, 2015 ... announced it has earned three Gold, three Silver, and ... Business Awards gala held in Chicago ... recognized as the premier business awards program in the ... and recognizes our company,s strength in developing leaders, cultivating ...
Breaking Biology Technology:Luzi Smart Lamp Recently Launched Indiegogo Campaign 2Luzi Smart Lamp Recently Launched Indiegogo Campaign 3AgBiome and Genective collaborate to create novel insect-resistant crops 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 2Strand Life Sciences Names Scott A. Storrer CEO as Company Continues Global Expansion with Focus on Precision Medicine Product 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3
... Agendia BV, a,world leader in the rapidly evolving field ... Officer Laura van ,t Veer has,received a prestigious 2007 ... Cancer Research Foundation. The Pink Ribbon ,Breast Cancer ... breast cancer researchers with a total value of,32 M$. ...
... Oximetry Unit, NEW YORK, Oct. 22 SPO ... biosensor and microprocessor,technologies for use in portable monitoring devices, ... unit. This sales milestone has,been achieved within three years ... The bulk of the 100,000 units sold include the ...
... Holdings Asia and,its co-investors today announced that they ... the world,s largest privately held,crop- protection and life-science ... billion (US$2.2 billion). The sale will culminate a,five-year ... private,equity firm with investment teams in Japan, Greater ...
Cached Biology Technology:Agendia BV Announces That its Chief Research Officer Laura van 't Veer has Received a 2007 Breast Cancer Research Foundation Award 2SPO Medical Announces Major Sales Milestone 2SPO Medical Announces Major Sales Milestone 3Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 2Olympus Capital Announces Agreement to Sell Arysta LifeScience Corporation 3
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
(Date:6/16/2015)... 16, 2015  With the increasing number and severity ... top concern. The recent compromise of Federal employee ... strong authentication within government agencies. HYPR Corp. ... password (OTP) authenticator, has been submitted for testing and ... 3 validation for tamper proofing. The ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 2Government Ready Biometric Security Approaching as HYPR Corp. Files FIPS 140-2 Level 3 Validation for Its Proprietary Biometric Token 3
... in which the aging process is linked to DNA damage--which ... influences--and the various ways in which cells repair that damage. ... fruit flies make use of a different mix of molecular ... are reported by William Engels and colleagues at the University ...
... “vile and cynical exploitation?by the alternative medicines industry, argues a ... that up to 80% of all patients with cancer take ... treat their cancer, writes Jonathan Waxman, Professor of Oncology at ... use of many of these approaches is obtuse ?one might ...
... The widely used breast cancer drug tamoxifen (Nolvadex®), which ... full strength indefinitely if used along with a second ... investigators from the National Cancer Institute (NCI), part of ... results appear in the December 11, 2006, issue of ...
Cached Biology News:Age-related changes in DNA repair illuminate the connection between age and genetic damage 2Protect patients from exploitation by alternative medicines industry 2Restoring tamoxifen sensitivity in resistant breast cancer cells 2